LP

LB Pharmaceuticals Inc Common Stock

LBRX·NASDAQ

$27.95

+3.4%
HealthcareBiotechnology

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

At a Glance

Live Snapshot
Market Cap$801.51M
EPS-1.0000
P/E Ratio-27.95
Earnings Date06/25/2026

lbrx

Interest Expense

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

LP

LB Pharmaceuticals Inc Common Stock Competitors Analysis of Interest Expense

LBRX · NASDAQ
CompanyInterest Expense
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
0.00
N/AN/AN/A
ANNX logo
Annexon, Inc.
NASDAQ:ANNX
0.00
N/AN/AN/A
6.17M
N/AN/AN/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
11.25M
19.5%20.9%N/A
489.00K
37.8%177.0%N/A
0.00
N/AN/AN/A
7.89M
23.8%20.9%N/A
0.00
N/AN/AN/A
1.89M
0.3%-20.3%2.9%
KRRO logo
Korro Bio, Inc.
NASDAQ:KRRO
0.00
N/AN/AN/A
LP

LB Pharmaceuticals Inc Common Stock Fair Value Envelope

LBRX · NASDAQ

Our analysis suggests that LBRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.95, this represents a potential HIDDEN relative to our calculated worth for LB Pharmaceuticals Inc Common Stock.

Intrinsic Value
Current Price: $27.95